Oruka Therapeutics (NASDAQ:ORKA) and Cardio Diagnostics (NASDAQ:CDIO) Critical Contrast

Cardio Diagnostics (NASDAQ:CDIO) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Cardio Diagnostics and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-22,358.43%	-312.97%	-189.57%
Oruka Therapeutics	N/A	-20.18%	-19.51%

Risk & Volatility

Cardio Diagnostics has a beta of 4.87, indicating that its stock price is 387% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Institutional and Insider Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cardio Diagnostics and Oruka Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$39,138.00	156.50	-$8.38 million	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$5.34 million	N/A	N/A

Oruka Therapeutics has lower revenue, but higher earnings than Cardio Diagnostics.

Analyst Recommendations

This is a summary of current ratings and price targets for Cardio Diagnostics and Oruka Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0	0	1	0	3.00
Oruka Therapeutics	0	0	4	2	3.33

Cardio Diagnostics presently has a consensus target price of $2.00, suggesting a potential upside of 640.74%. Oruka Therapeutics has a consensus target price of $41.25, suggesting a potential upside of 67.82%. Given Cardio Diagnostics’ higher probable upside, analysts clearly believe Cardio Diagnostics is more favorable than Oruka Therapeutics.

Summary

Oruka Therapeutics beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.